Cat. No.: HY-B0987

Ascorbyl palmitate

(Synonyms: L-Ascorbic acid 6-hexadecanoate; 6-O-Palmitoyl-L-ascorbic acid)

3 Cited Publications

Customer Review

Based on 3 publication(s) in Google Scholar

Ascorbyl palmitate is an orally active ester formed from ascorbic acid and palmitic acid, used as an antioxidant and food additive. Ascorbyl palmitate in preventing fat and oil oxidation is more efficient than Butylated hydroxyanisole (HY-B1066) and Butylated hydroxytoluene (HY-Y0172). Ascorbyl palmitate mitigates inhibition of collagen synthesis by select calcium and sodium channel blockers. Ascorbyl palmitate induces Apoptosis in human umbilical vein endothelial cells (HUVECs). Ascorbyl palmitate ameliorates inflammatory diseases by inhibition of NLRP3 inflammasome.

For research use only. We do not sell to patients.

Purity: 99.62%
CAS No.: 137-66-6
Formula: C₂₂H₃₈O₇
Molecular Weight:414.53

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Ascorbyl palmitate Chemical Structure

CAS No.: 137-66-6

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (3)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

All Calcium Channel Isoforms :

All Endogenous Metabolite Isoforms :

All Caspase Isoforms :

All Sodium Channel Isoforms :

All Bcl-2 Family Isoforms :

All NOD-like Receptor (NLR) Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
RD	EC₅₀	>240 μM Compound: PAA	Antiviral activity against Herpes simplex virus type 1 infected in human RD cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Herpes simplex virus type 1 infected in human RD cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 22390834]

In Vitro

Ascorbyl palmitate (25-400 μM, 24 h and 48 h) induces cell cytotoxicity and inhibits cell growth in HUVECs in a dose- and time-dependent manner^[1].
Ascorbyl palmitate (125 μM, 24 h and 48 h) inhibits proliferation of HUVECs and induces cell death by inducing apoptosis, which decreases Bcl-2 gene expression ratio and increases Caspase-3, 9 activities in HUVECs^[1].
Ascorbyl palmitate (1.25-20 μM, 72 h) dependent extracellular matrix (ECM) deposition of collagen type l is significantly reduced in aortic smooth muscle cells, which is inhibited by Nifedipine (HY-B0284) (50 µM, 72 h)^[2].
Ascorbyl palmitate (0-20 μM, 1 h) has stronger inhibitory activity against NLRP3 inflammasome through its antioxidant ability than ascorbic acid in LPS (HY-D1056)-primed bone marrow-derived macrophages (BMDMs)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

Human umbilical vein endothelial cells (HUVECs)
Concentration:

25-400 μM
Incubation Time:

24 h and 48 h
Result:

Inhibited cell growth after 24h and 48 h with IC₅₀ values of 440 µM and 125 µM, respectively in HUVECs.

Immunofluorescence^[1]

Cell Line:

HUVECs
Concentration:

125 μM
Incubation Time:

24 h and 48 h
Result:

Resulted that DNA fragmentation which was sign of Apoptosis induction was obvious.

Real Time qPCR^[1]

Cell Line:

HUVECs
Concentration:

125 μM
Incubation Time:

24 h and 48 h
Result:

Decreased Bcl-2 gene expression ratio and increased Caspase-3, 9 activities in HUVECs.

Western Blot Analysis^[3]

Cell Line:

Mouse BMDMs
Concentration:

5-20 μM
Incubation Time:

1 h
Result:

Dose-dependently inhibited the cleavage of caspase-1 in BMDMs.

In Vivo

Ascorbyl palmitate (25 mg/kg, i.p., every 2 days for 10 or 14 days) alleviates LPS (HY-D1056)-induced NLRP3 inflammasome activation, dextran sulfate sodium (DSS) (HY-116282C)-induced colitis and experimental autoimmune encephalomyelitis (EAE) in mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Mice administrated with 2.5 % (w/v) DSS in drinking water for 6 days to induse colitis^[3]
Dosage:

25 mg/kg
Administration:

i.p., every 2 days for 10 days
Result:

Reduced the IL-1β production in serum, colon shortening, loss of goblet cells, destruction of intestinal epithelium structure, infiltration of inflammatory cells in mice with DSS-induced colitis.

Animal Model:

Mice immunized with MOG35-55 (HY-P1240) peptide (300 μg, s.c.) on day 0 and Pertussis toxin (HY-112779) (700 ng, i.v.) on days 0 and 2 to induce EAE^[3]
Dosage:

25 mg/kg
Administration:

i.p., every 2 days for 14 days
Result:

Decreased the expression levels of proin-flammatory cytokines, including IL-1β, IL-6, TNF-α in the spinal cord of mice.

Chemical Information

CAS No. 137-66-6
Appearance Solid
Molecular Weight 414.53
Formula C₂₂H₃₈O₇
Color White to off-white
SMILES

OC([C@H](O1)[C@H](COC(CCCCCCCCCCCCCCC)=O)O)=C(O)C1=O
Synonyms

L-Ascorbic acid 6-hexadecanoate; 6-O-Palmitoyl-L-ascorbic acid
Structure Classification
- Others
Initial Source
- Endogenous metabolite
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (3)

All

Sort by:

Journal Impact Factor

Cell

Distinct longevity mechanisms across and within species and their association with aging. [Abstract]

2023 Jun 22;186(13):2929-2949.e20. PMID: 37269831
Cell Metab

Identification and Application of Gene Expression Signatures Associated with Lifespan Extension. [Abstract]

2019 Sep 3;30(3):573-593.e8. PMID: 31353263
The Pennsylvania State University

2023 May 30.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (241.24 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4124 mL

12.0619 mL

24.1237 mL

5 mM

0.4825 mL

2.4124 mL

4.8247 mL

10 mM

0.2412 mL

1.2062 mL

2.4124 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.03 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Sohrabi Y, et al. Cytotoxicity and Genotoxicity Assessment of Ascorbyl Palmitate (AP) Food Additive[J]. Adv Pharm Bull. 2018 Jun;8(2):341-346. [Content Brief]

[2]. Ivanov V, et al. Inhibition of collagen synthesis by select calcium and sodium channel blockers can be mitigated by ascorbic acid and ascorbyl palmitate. Am J Cardiovasc Dis. 2016 May 18;6(2):26-35. [Content Brief]

[3]. Zhang L, et al. Ascorbyl palmitate ameliorates inflammatory diseases by inhibition of NLRP3 inflammasome[J]. Int Immunopharmacol. 2024 Apr 20;131:111915. [Content Brief]

[4]. Jonker D, et al. Comparison of the effects of ascorbyl palmitate and L-ascorbic acid on paracetamol-induced hepatotoxicity in the mouse[J]. Toxicology. 1988 Nov 30;52(3):287-95. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4124 mL	12.0619 mL	24.1237 mL	60.3093 mL
	5 mM	0.4825 mL	2.4124 mL	4.8247 mL	12.0619 mL
	10 mM	0.2412 mL	1.2062 mL	2.4124 mL	6.0309 mL
	15 mM	0.1608 mL	0.8041 mL	1.6082 mL	4.0206 mL
	20 mM	0.1206 mL	0.6031 mL	1.2062 mL	3.0155 mL
	25 mM	0.0965 mL	0.4825 mL	0.9649 mL	2.4124 mL
	30 mM	0.0804 mL	0.4021 mL	0.8041 mL	2.0103 mL
	40 mM	0.0603 mL	0.3015 mL	0.6031 mL	1.5077 mL
	50 mM	0.0482 mL	0.2412 mL	0.4825 mL	1.2062 mL
	60 mM	0.0402 mL	0.2010 mL	0.4021 mL	1.0052 mL
	80 mM	0.0302 mL	0.1508 mL	0.3015 mL	0.7539 mL
	100 mM	0.0241 mL	0.1206 mL	0.2412 mL	0.6031 mL

Ascorbyl palmitate

3 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Ascorbyl palmitate

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Membrane Transporter/Ion Channel Compound Library

Metabolism/Protease Compound Library

Neuronal Signaling Compound Library

NF-κB Signaling Compound Library

Natural Product Library

Anti-Aging Compound Library

Antioxidant Compound Library

Oxygen Sensing Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Blood Cancer Compound Library

Mitochondria-Targeted Compound Library

Food Additive Library

Inactive Ingredient Library

Antidepressant Compound Library

Coagulation and Anti-coagulation Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cell Death Library

Ion Channel Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Inflammasomes related Compound Library

Multi-Target Compound Library

Radioprotector Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Dietary Supplement Library

Vitamin Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Cosmetic Ingredient Compound Library

Pattern Recognition Receptors Library

Environmental Pollutant Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Ascorbyl palmitate

All Calcium Channel Isoforms

All Endogenous Metabolite Isoforms

All Caspase Isoforms

All Sodium Channel Isoforms

All Bcl-2 Family Isoforms

All NOD-like Receptor (NLR) Isoforms

Biological Activity

Chemical Information

Publications (3)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Ascorbyl palmitate Related Classifications

Cat. No.: HY-B0987